EPA:ALSEN - Euronext Paris - Matif - FR0012596468 - Common Stock - Currency: EUR
EPA:ALSEN (3/7/2025, 7:00:00 PM)
0.57
-0.01 (-2.4%)
The current stock price of ALSEN.PA is 0.57 EUR. In the past month the price decreased by -10.38%. In the past year, price decreased by -34.86%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 61 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
SENSORION SA
375, rue du Professeur Joseph Blayac
Montpellier OCCITANIE FR
Employees: 61
Company Website: https://www.sensorion-pharma.com/
Investor Relations: http://sensorion.com/en/investors/
Phone: 33467207730
The current stock price of ALSEN.PA is 0.57 EUR. The price decreased by -2.4% in the last trading session.
The exchange symbol of SENSORION SA is ALSEN and it is listed on the Euronext Paris - Matif exchange.
ALSEN.PA stock is listed on the Euronext Paris - Matif exchange.
12 analysts have analysed ALSEN.PA and the average price target is 2.42 EUR. This implies a price increase of 325% is expected in the next year compared to the current price of 0.57. Check the SENSORION SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SENSORION SA (ALSEN.PA) has a market capitalization of 171.28M EUR. This makes ALSEN.PA a Micro Cap stock.
SENSORION SA (ALSEN.PA) currently has 61 employees.
SENSORION SA (ALSEN.PA) has a resistance level at 0.59. Check the full technical report for a detailed analysis of ALSEN.PA support and resistance levels.
The Revenue of SENSORION SA (ALSEN.PA) is expected to grow by 299.94% in the next year. Check the estimates tab for more information on the ALSEN.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALSEN.PA does not pay a dividend.
SENSORION SA (ALSEN.PA) will report earnings on 2025-03-12, after the market close.
SENSORION SA (ALSEN.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).
ChartMill assigns a fundamental rating of 3 / 10 to ALSEN.PA. The financial health of ALSEN.PA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ALSEN.PA reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 63.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -23.31% | ||
ROE | -28.36% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 87% to ALSEN.PA. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 58.14% and a revenue growth 299.94% for ALSEN.PA